Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2011

View Archived Issues

Lupeol curbs growth of androgen-dependent and castration-resistant prostate cancer cells

New nonelectrophilic reference agonist discovered to assess TRPA1 channel pharmacology

Pilot trial evaluates Flebogamma DIF in patients with Alzheimer's disease

Novel protein Wnt signaling pathway inhibitors synthesized at Epitherix

Merck & Co. claims new muscarinic acetylcholine M1 receptor modulators

Researchers at Sanofi present novel kinesin-like protein KIF11 inhibitors

SuppreMol and Protagen to identify therapy-related biomarkers in patients with SLE

Takeda patents new melanin-concentrating hormone MCH1 receptor antagonists

Akorn announces partnership with Aciex Therapeutics

Novel series of histamine H3 receptor antagonists presented

Novartis enrolls patients in phase II BPS-804 trials

Korean company prepares new AMPK activators

Merck & Co. and Serum Institute of India to develop pneumococcal conjugate vaccine

Zoely is approved in the E.U.

Interim data reported from phase I/II trial of ProSavin

Agreement reached on design of phase III Rhucin study in hereditary angioedema

New serum biomarker to predict response to IFN-beta therapy in MS

FDA accepts ruxolitinib NDA filing for myelofibrosis

FDA issues warning regarding chronic high-dose fluconazole therapy

Phase III ragweed allergy immunotherapy tablet studies meet primary endpoints

Sanofi recruits patients for phase II SAR-279356 trial

NPS Pharmaceuticals and GSK form new calcilytics agreement

Enrollment begins in phase IIb/III study of masitinib in rheumatoid arthritis

Thrombotech begins enrollment in phase IIa trial of lead product in ischemic stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...